Most-Upgraded Stocks NASDAQ:REGN Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $819.35 -7.62 (-0.92%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$818.29▼$835.0050-Day Range$715.57▼$826.9752-Week Range$538.01▼$835.00Volume459,228 shsAverage Volume647,764 shsMarket Capitalization$89.58 billionP/E Ratio21.43Dividend YieldN/APrice Target$844.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Regeneron Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside2.0% Upside$835.57 Price TargetShort InterestHealthy1.16% of Float Sold ShortDividend StrengthN/ASustainability-1.68Upright™ Environmental ScoreNews Sentiment0.63Based on 61 Articles This WeekInsider TradingSelling Shares$22.95 M Sold Last QuarterProj. Earnings Growth5.86%From $34.11 to $36.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector304th out of 999 stocksPharmaceutical Preparations Industry128th out of 489 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.74, and is based on 18 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $835.57, Regeneron Pharmaceuticals has a forecasted upside of 2.0% from its current price of $819.35.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.16% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 0.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 64.79% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Rheumatoid arthritis medication", and "Anakinra" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -1.68. Previous Next 2.0 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 61 news articles for Regeneron Pharmaceuticals this week, compared to 11 articles on an average week.Social Mentions This WeekMarketBeat has tracked 1 reddit mention for Regeneron Pharmaceuticals this week, compared to 0 mentions on an average week.Search InterestOnly 27 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -42% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,950,981.00 in company stock.Percentage Held by InsidersOnly 8.99% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions84.25% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.86% in the coming year, from $34.11 to $36.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 21.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 21.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.04.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.83. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Regeneron Pharmaceuticals (NASDAQ:REGN) StockRegeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.Read More Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock News HeadlinesMarch 27, 2023 | marketbeat.comSanofi, Regeneron Shares Pop On Big News About COPD Treatment (REGN)Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.March 29, 2023 | finance.yahoo.comLibtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)March 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 29, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Lowered by SVB LeerinkMarch 29, 2023 | americanbankingnews.comGeorge Yancopoulos Sells 3,656 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMarch 29, 2023 | americanbankingnews.comInsider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells 1,240 Shares of StockMarch 28, 2023 | benzinga.comRegeneron Pharmaceuticals Unusual Options Activity For March 28March 28, 2023 | finance.yahoo.comUnity (UNX) Down on Disappointing Results From Wet AMD StudyMarch 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 28, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by SVB Leerink to "Outperform"March 28, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on Regeneron Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:REGN)March 27, 2023 | marketwatch.comS&P 500 Analyst Moves: REGNMarch 27, 2023 | msn.comSanofi, Regeneron Shares Pop On Big News About COPD TreatmentMarch 27, 2023 | msn.comSVB Leerink Upgrades Regeneron Pharmaceuticals (REGN)March 27, 2023 | finance.yahoo.comUPDATE 2-U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patentsMarch 27, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at SVB SecuritiesMarch 27, 2023 | finance.yahoo.comAmgen bid to revive cholesterol drug patents comes to U.S. Supreme CourtMarch 27, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,040.00March 26, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Raised to Market Perform at Raymond JamesMarch 25, 2023 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $800.00 by Analysts at Robert W. BairdMarch 25, 2023 | americanbankingnews.comBarclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $915.00March 25, 2023 | americanbankingnews.comEF Hutton Acquisition Co. I Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $862.00March 24, 2023 | msn.comRaymond James Upgrades Regeneron Pharmaceuticals (REGN)March 24, 2023 | msn.comJefferies Upgrades Regeneron Pharmaceuticals (REGN)March 24, 2023 | markets.businessinsider.comRegeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving InMarch 24, 2023 | finance.yahoo.comBiotech Growth Stock Soars To New Highs On Lung Disease BreakthroughMarch 24, 2023 | finance.yahoo.comRegeneron’s Asthma Drug Results Were ‘Stellar.’ Analyst Sees a Sales Bonanza.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Company Calendar Last Earnings2/03/2023Today3/29/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees11,851Year Founded1988Price Target and Rating Average Stock Price Forecast$835.57 High Stock Price Forecast$1,040.00 Low Stock Price Forecast$625.00 Forecasted Upside/Downside+2.7%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$38.24 Trailing P/E Ratio21.49 Forward P/E Ratio24.09 P/E Growth2.83Net Income$4.34 billion Net Margins35.64% Pretax Margin39.92% Return on Equity22.87% Return on Assets17.54% Debt Debt-to-Equity Ratio0.12 Current Ratio5.06 Quick Ratio4.29 Sales & Book Value Annual Sales$12.17 billion Price / Sales7.38 Cash Flow$44.61 per share Price / Cash Flow18.42 Book Value$207.31 per share Price / Book3.96Miscellaneous Outstanding Shares109,330,000Free Float99,498,000Market Cap$89.83 billion OptionableOptionable Beta0.21 Social Links Key ExecutivesLeonard S. SchleiferCo-President, Chief Executive Officer & DirectorGeorge Damis YancopoulosCo-President, Director & Chief Scientific OfficerPatrice GiloolySenior VP-Quality Assurance & OperationsRobert E. LandryChief Financial Officer & Executive VP-FinanceNeil StahlExecutive VP-Research & DevelopmentKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXAlnylam PharmaceuticalsNASDAQ:ALNYGSKNYSE:GSKZoetisNYSE:ZTSTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsBonnie L BasslerSold 1,240 sharesTotal: $1.01 M ($818.00/share)George YancopoulosSold 3,656 sharesTotal: $2.94 M ($804.26/share)MetLife Investment Management LLCSold 509 shares on 3/23/2023Ownership: 0.026%Christopher R FenimoreSold 2,192 sharesTotal: $1.77 M ($806.47/share)ETF Managers Group LLCBought 3,587 shares on 3/23/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions REGN Stock - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price forecast for 2023? 23 brokers have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $625.00 to $1,040.00. On average, they predict the company's stock price to reach $835.57 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2023? Regeneron Pharmaceuticals' stock was trading at $721.49 at the start of the year. Since then, REGN stock has increased by 14.1% and is now trading at $823.43. View the best growth stocks for 2023 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, beating the consensus estimate of $8.18 by $4.38. The biopharmaceutical company had revenue of $3.41 billion for the quarter, compared to analysts' expectations of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a trailing twelve-month return on equity of 22.87%. The business's revenue was down 31.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $23.72 earnings per share. Read the conference call transcript. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), VanEck Biotech ETF (BBH), ProShares Ultra Nasdaq Biotechnology (BIB), Formidable Fortress ETF (KONG), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Simplify Health Care ETF (PINK). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (2.02%), Price T Rowe Associates Inc. MD (1.58%), Putnam Investments LLC (1.02%), American Century Companies Inc. (1.01%), Norges Bank (0.88%) and Morgan Stanley (0.81%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $823.43. How much money does Regeneron Pharmaceuticals make? Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $90.03 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $38.24 on an earnings per share basis. How many employees does Regeneron Pharmaceuticals have? The company employs 11,851 workers across the globe. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113. This page (NASDAQ:REGN) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.